Research

Compound Similar to Diabetic Medications Slows Parkinson’s Progression in Mouse Study

An investigative compound similar to those used to treat diabetes was able to slow Parkinson’s progression and ease behavioral symptoms associated with the disease in mouse models. The compound, called NLY01 and developed by scientists at Johns Hopkins Medicine, works to protect against the loss of dopaminergic nerve cells — directly targeting a cause of Parkinson’s progression — and may enter…

Continue Reading

Research

Michael J. Fox Foundation Grants $7.7M for New Parkinson’s Research

New research projects focused on better ways to monitor and treat Parkinson’s disease were awarded funding recently by the Michael J. Fox Foundation (MJFF). From more than 200 funding proposals submitted to its 2018 spring funding program, 39 projects were funded. Selected projects primarily come from the United States (19), but funding also was granted to projects in 11 other…

Continue Reading

Research

Deep Brain Stimulation Seen to Ease Tremors in Patients with Early-stage Disease in Pilot Study

Deep brain stimulation (DBS) was seen to slow the progression of “rest tremors”  in patients with early-stage Parkinson’s disease, a pilot study reports. The study, “Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease,” was published in Neurology. “The finding around tremor is truly exceptional,” David Charles, MD,  professor and vice-chair of neurology at Vanderbilt University,…

Continue Reading

Research

Earlier Parkinson’s Onset and Dystonia Symptoms Seen in GCH1 Mutations in Study

Earlier disease onset and involuntary foot muscle contractions may be a consequence of mutations in the GCH1 gene in both Parkinson’s patients and those with dopa-responsive dystonia (DRD), a study reports. These mutations may also explain the lack of problems found with the autonomic nervous system — which controls organs not under conscious control, such as the heart, stomach, and intestines — and stable cognitive…

Continue Reading

Research

Back to Medications

Haven’t I been here before? I can’t fight this alone. Medications are now an option. Several months on a holistic route gave me no improvement in symptoms. So, I bit the bullet and decided to try another Parkinson’s prescription medication. In October 2017, I started the Neupro (rotigotine) transdermal patch. This bypasses the digestive system (hence, less chance of nausea) because…

Continue Reading

Research

How Hallucinations Affect Patients and Caregivers Over Disease Course Focus of Study

Visual hallucinations can be common in Parkinson’s patients and others with dementia, but the degree of distress they cause is greatly influenced by the person’s ability to understand and consider them — and have the cognitive resources to do so, a study reports. Likewise, the tailored support given patients needs to reflect their ability to understand and manage this disease symptom. The…

Continue Reading

Research

Tips from the Pros: Maintaining Cognitive Brain Health in Parkinson’s Disease

Maintaining cognitive brain health is a high priority for both people with Parkinson’s disease (PD) and family members. Though many living with Parkinson’s will not develop dementia, mild cognitive issues may emerge in 20 to 50 percent. Through the Parkinson’s Foundation Community Choice Research Award program, which awards research grants based on the insights of people in the Parkinson’s community, …

Continue Reading

Research

The ABCs of Parkinson’s Disease: The Letter C

Third in a series. Read part one and two. In this column, the letter C is for cognitive changes and caregiving. Cognitive changes Some possible Parkinson’s disease symptoms are obvious because they are visible: tremors, abnormal gait, a non-swinging arm. You can see them. Others can see them. But some symptoms are not so obvious because they are invisible: internal tremors,…

Continue Reading

Research

Once-a-day Capsule for Nuplazid and Lower Dose Option Approved for Parkinson’s Psychosis Patients

The U.S. Food and Drug Administration has approved a once-a-day capsule formulation and a lower tablet strength for Nuplazid (pimavanserin), a treatment for the hallucinations and delusions associated with Parkinson’s psychosis. The new formulation — a 34 mg capsule— enables patients to take the recommended oral dose once a day instead of the twice-daily existing 17-mg tablet dose. Also approved…

Continue Reading